Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs

(2012) H. Agersø et al.   HAEMOPHILIA

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

(2011) C. Negrier et al.   BLOOD

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

(2011) U. MARTINOWITZ et al.   HAEMOPHILIA

PEGylation of therapeutic proteins

(2010) Simona Jevševar et al.   Biotechnology Journal

Prophylaxis in the haemophilia population

(2010) V. S. BLANCHETTE   HAEMOPHILIA

Purification and characterization of a new recombinant factor VIII (N8)

(2009) L. THIM et al.   HAEMOPHILIA

Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience

(2008) C. E. NEUNERT et al.   HAEMOPHILIA

The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics

(2008) C.Simone Fishburn   JOURNAL OF PHARMACEUTICAL SCIENCES

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

(2008) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS